Chemical Engineering @ChemengFiles.Com

The antidepressant melatonérgico - Valdoxan (R) / Thymanax (R) (agomelatina) - received a positive opinion of the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMEA) for the use of the treatment of adult patients with acute depressive disorder (MDD). Following approval by the European Commission in early 2009, Servier Valdoxan marketed in Europe in the coming months.

The antidepressant melatonérgico - Valdoxan (R) / Thymanax (R) (agomelatina) - received a positive opinion of the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency (EMEA) for the use of the treatment of adult patients with acute depressive disorder (MDD). Following approval by the European Commission in early 2009, Servier Valdoxan marketed in Europe in the coming months.

Episteme Plc has announced that they have signed a research collaboration agreement with Novartis for development and identifying new drug targets and therapeutics through a wide variety of diseases. The collaboration combines the expertise of episteme in stem cells and a drug discovery program with Novartis in the vision of new ways of
disease and bioinformatics.

Episteme Plc has announced that they have signed a research collaboration agreement with Novartis for development and identifying new drug targets and therapeutics through a wide variety of diseases. The collaboration combines the expertise of episteme in stem cells and a drug discovery program with Novartis in the vision of new ways of
disease and bioinformatics.

Helsinn with the Irish Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan TD, announced that Helsinn Holding SA will establish a center of excellence in research and development for oral solid dosage (OSD) in its plant Helsinn Birex Pharmaceuticals, one of four companies on site at Mulhuddart (Dublin). The investment of over EUR 13 million is backed by the government through IDA Ireland, and plans to create 10 posts of high research value. Helsinn's main business is the licensee of the late stage pharmaceutical compounds in therapeutic niche areas for development and subsequent manufacturing and distribution business. The company operates primarily in cancer palliative care, gastrointestinal and anti-inflammatory treatments. The investment is part of the strategic decision to strengthen their capacity Helsinn internal development.

The Tánaiste said: "This investment will establish the Irish operation as the Center for Knowledge and Learning for products in the OSD Helsinn Group and also the site of launch for new products within its portfolio. Strategically it is very important for the Irish operation, located in the center of R & D Helsinn. The investment is in line with the government's strategy of eIDA detransformación existing Irish operations of international companies, especially in R & D and knowledge-based activities. "

Helsinn with the Irish Tánaiste and Minister for Enterprise, Trade and Employment Mary Coughlan TD, announced that Helsinn Holding SA will establish a center of excellence in research and development for oral solid dosage (OSD) in its plant Helsinn Birex Pharmaceuticals, one of four companies on site at Mulhuddart (Dublin). The investment of over EUR 13 million is backed by the government through IDA Ireland, and plans to create 10 posts of high research value. Helsinn's main business is the licensee of the late stage pharmaceutical compounds in therapeutic niche areas for development and subsequent manufacturing and distribution business. The company operates primarily in cancer palliative care, gastrointestinal and anti-inflammatory treatments. The investment is part of the strategic decision to strengthen their capacity Helsinn internal development.

The Tánaiste said: "This investment will establish the Irish operation as the Center for Knowledge and Learning for products in the OSD Helsinn Group and also the site of launch for new products within its portfolio. Strategically it is very important for the Irish operation, located in the center of R & D Helsinn. The investment is in line with the government's strategy of eIDA detransformación existing Irish operations of international companies, especially in R & D and knowledge-based activities. "